Evidence map›Paper›PMID 37675119›Full record

ArticleFrontiers in immunology2023

Glycolytic reprogramming in macrophages and MSCs during inflammation.

Xueping Li, Huaishuang Shen, Mao Zhang, Victoria Teissier, Ejun Elijah Huang, Qi Gao, Masanori Tsubosaka, Masakazu Toya, Junichi Kushioka, Chima V Maduka and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Xueping LiDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Huaishuang ShenDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Mao ZhangCardiovascular Institute Operations, Stanford University School of Medicine, Stanford, CA, United States.
Victoria TeissierDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Ejun Elijah HuangDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Qi GaoDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Masanori TsubosakaDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Masakazu ToyaDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Junichi KushiokaDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Chima V MadukaDepartments of Biomedical Engineering and Microbiology & Molecular Genetics, Michigan State University, East Lansing, MI, United States.
Christopher H ContagDepartments of Biomedical Engineering and Microbiology & Molecular Genetics, Michigan State University, East Lansing, MI, United States.
Simon Kwoon-Ho ChowDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Ning ZhangDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Stuart B GoodmanDepartment of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, United States.
Stanford University · USMichigan State University · USChinese University of Hong Kong · CNSoochow University · CN

Funding

Wear Particle Disease and NF-kappa B SignalingR01AR063717 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2012 to 2021
$3.5M
Customized MSCs to Enhance Healing of Bone DefectsR01AR073145 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2018 to 2021
$1.4M
NIAMS NIH HHS R01 AR063717NIAMS NIH HHS R01 AR073145
6 · The paper itself

Abstract

Background: Dysregulated inflammation is associated with many skeletal diseases and disorders, such as osteolysis, non-union of fractures, osteonecrosis, osteoarthritis and orthopaedic infections. We previously showed that continuous infusion of lipopolysaccharide (LPS) contaminated polyethylene particles (cPE) caused prolonged inflammation and impaired bone formation. However, the metabolic and bioenergetic processes associated with inflammation of bone are unknown. Mitochondria are highly dynamic organelles that modulate cell metabolism and orchestrate the inflammatory responses that involve both resident and recruited cells. Glycolytic reprogramming, the shift from oxidative phosphorylation (OXPHOS) to glycolysis causes inappropriate cell activation and function, resulting in dysfunctional cellular metabolism. We hypothesized that impaired immunoregulation and bone regeneration from inflammatory states are associated with glycolytic reprogramming and mitochondrial dysfunction in macrophages (Mφ) and mesenchymal stromal cells (MSCs). Methods: We used the Seahorse XF96 analyzer and real-time qPCR to study the bioenergetics of Mφ and MSCs exposed to cPE. To understand the oxygen consumption rate (OCR), we used Seahorse XF Cell Mito Stress Test Kit with Seahorse XF96 analyzer. Similarly, Seahorse XF Glycolytic Rate Assay Kit was used to detect the extracellular acidification rate (ECAR) and Seahorse XF Real-Time ATP Rate Assay kit was used to detect the real-time ATP production rates from OXPHOS and glycolysis. Real-time qPCR was performed to analyze the gene expression of key enzymes in glycolysis and mitochondrial biogenesis. We further detected the gene expression of proinflammatory cytokines in Mφ and genes related to cell differentiation in MSC during the challenge of cPE. Results: Our results demonstrated that the oxidative phosphorylation of Mφ exposed to cPE was significantly decreased when compared with the control group. We found reduced basal, maximal and ATP-production coupled respiration rates, and decreased proton leak in Mφ during challenge with cPE. Meanwhile, Mφ showed increased basal glycolysis and proton efflux rates (PER) when exposed to cPE. The percentage (%) of PER from glycolysis was higher in Mφ exposed to cPE, indicating that the contribution of the glycolytic pathway to total extracellular acidification was elevated during the challenge of cPE. In line with the results of OCR and ECAR, we found Mφ during cPE challenge showed higher glycolytic ATP (glycoATP) production rates and lower mitochondrial ATP (mitoATP) production rates which is mainly from OXPHOS. Interestingly, MSCs showed enhanced glycolysis during challenge with cPE, but no significant changes in oxygen consumption rates (OCR). In accordance, seahorse assay of real-time ATP revealed glycoATP rates were elevated while mitoATP rates showed no significant differences in MSC during challenge with cPE. Furthermore, Mφ and MSCs exposed to cPE showed upregulated gene expression levels of glycolytic regulators and Mφ exposed to cPE expressed higher levels of pro-inflammatory cytokines. Conclusion: This study demonstrated the dysfunctional bioenergetic activity of bone marrow-derived Mφ and MSCs exposed to cPE, which could impair the immunoregulatory properties of cells in the bone niche. The underlying molecular defect related to disordered mitochondrial function could represent a potential therapeutic target during the resolution of inflammation.

Indexed as

Mesenchymal Stem CellsProtonsAdenosine TriphosphateCytokinesGlycolysisHumansInflammationMacrophagesAdenosine TriphosphateCytokinesProtonsbone marrow-derived cellsinflammationmacrophagemesenchymal stromal cellmitochondrial bioenergetics

Identifiers

PMID37675119
PMCPMC10477714
OpenAlexW4386073659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.